- Home
- XBIO vs CHEK Comparison
XBIO vs CHEK Comparison
Compare XBIO & CHEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIO
- CHEK
- Stock Information
- Founded
- XBIO N/A
- CHEK 2004
- Country
- XBIO United States
- CHEK Israel
- Employees
- XBIO N/A
- CHEK N/A
- Industry
- XBIO Biotechnology: Pharmaceutical Preparations
- CHEK Medical Electronics
- Sector
- XBIO Health Care
- CHEK Health Care
- Exchange
- XBIO Nasdaq
- CHEK Nasdaq
- Market Cap
- XBIO 5.8M
- CHEK 5.1M
- IPO Year
- XBIO N/A
- CHEK 2015
- Fundamental
- Price
- XBIO $3.66
- CHEK $0.80
- Analyst Decision
- XBIO Hold
- CHEK
- Analyst Count
- XBIO 1
- CHEK 0
- Target Price
- XBIO N/A
- CHEK N/A
- AVG Volume (30 Days)
- XBIO 30.0K
- CHEK 29.4K
- Earning Date
- XBIO 11-12-2024
- CHEK 11-25-2024
- Dividend Yield
- XBIO N/A
- CHEK N/A
- EPS Growth
- XBIO N/A
- CHEK N/A
- EPS
- XBIO N/A
- CHEK N/A
- Revenue
- XBIO $2,523,427.00
- CHEK N/A
- Revenue This Year
- XBIO N/A
- CHEK N/A
- Revenue Next Year
- XBIO N/A
- CHEK N/A
- P/E Ratio
- XBIO N/A
- CHEK N/A
- Revenue Growth
- XBIO 7.15
- CHEK N/A
- 52 Week Low
- XBIO $2.78
- CHEK $0.76
- 52 Week High
- XBIO $5.20
- CHEK $3.62
- Technical
- Relative Strength Index (RSI)
- XBIO 45.78
- CHEK 21.50
- Support Level
- XBIO $3.58
- CHEK $0.80
- Resistance Level
- XBIO $4.60
- CHEK $1.28
- Average True Range (ATR)
- XBIO 0.41
- CHEK 0.08
- MACD
- XBIO -0.02
- CHEK -0.02
- Stochastic Oscillator
- XBIO 7.48
- CHEK 7.57
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.
About CHEK Check-Cap Ltd.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.